TrialHuman vaccines & immunotherapeutics2026

Safety and immunogenicity of a booster dose of COVAC-2, a Sepivac SWE™ adjuvanted SARS-CoV-2 recombinant protein vaccine in previously vaccinated healthy adults; a randomized controlled multicentre trial.

Glenn Hamonic et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.